Application No. 10/551,052 Art Unit: 1651

AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior versions of claims in the application,

1. (Previously Presented) A substrate for culturing adherent cells, comprising:

a substrate coated with styrene/maleic anhydride copolymer (MAST) to which a cell

adhesion protein or peptide has been bound, the MAST being a hydrophobic binding-absorptive

polymer having a hydrophobic linear skeleton and a functional group that can react to a protein

or a peptide in a molecule.

2-16. (Cancelled)

17. (Withdrawn) The solidified preparation according to claim 1, wherein the binding is covalent

bonding formed by a reaction between a functional group, which is capable of reacting to a

protein or a peptide, of a hydrophobic binding-adsorptive polymer and a reactive group of a cell

adhesion protein or peptide.

18. (Withdrawn) The solidified preparation according to claim 17, wherein the covalent bonding

is amide bonding.

19. (Withdrawn/Currently Amended) The solidified preparation according to claim 17 or 18,

wherein the cell adhesion protein is fibronectin (FN), collagen (Col), laminin (LN) or vitronectin

(VN).

- 15 -

Application No. 10/551,052 Art Unit: 1651

20. (Withdrawn) The solidified preparation according to claim 17 or 18, wherein the cell

adhesion peptide is a peptide in a region relating to cell adhesion in an amino acid sequence of

the cell adhesion protein according to claim 19.

21. (Withdrawn/Currently Amended) The solidified preparation according to claim 20, wherein

the peptide in a region relating to cell adhesion of fibronectin (FN) protein is a peptide having a

specific Arg-Gly-Asp (RGD) amino acid sequence which binds to an integrin receptor on a cell

side.

22. (Withdrawn/Currently Amended) The solidified preparation according to claim 21, wherein

the peptide having the specific Arg-Gly-Asp an RGD amino acid sequence is (SEO ID NO: 16)

Tyr-Ala-Val Thr-Gly-Arg-Gly-Asp-Ser-Pro-Ala-Ser (FIB-1).

23. (Withdrawn/Currently Amended) The solidified preparation according to claim 20, wherein

the peptide in a region relating to cell adhesion of laminin (LN) protein is an α-chain G-domain

peptide.

24. (Withdrawn/Currently Amended) The solidified preparation according to claim 23, wherein

the G-domain peptide is Arg-Lys-Arg-Leu-Gln-Val-Gln-Leu-Ser-Ile-Arg-Thr (AG73) (SEO ID

NO: 1), Leu-Gln-Gln-Arg-Arg-Ser-Val-Leu-Arg-Thr-Lys-Ile (AG73T) (SEQ ID NO: 2), Thr-

- 16 -

Application No. 10/551,052 Art Unit: 1651

Leu-Gln-Leu-Gln-Glu-Gly-Arg Leu-His-Phe-Met (AG76.8) (SEQ ID NO: 17), Thr-Leu-Gln-Leu-Gln-Glu-Gly-Arg Leu-His Phe-Nle (AG76.8X) (SEQ ID NO: 18), Val-Lys-Thr-Glu-Tyr-Ile-Lys Arg Lys Ala Phe Met (AG81.2) (SEQ ID NO: 3), Val Lys Thr Glu Tyr Ile Lys Arg Lys Ala-Phe-Nle (AG81.2X) (SEQ ID NO: 4), Lys-Asn-Arg-Leu-Thr-lle-Glu-Leu-Glu-Val-Arg-Thr (A2G73) (SEQ ID NO: 5), Lys Pro Arg Leu Gln Phe Ser Leu Asp Ile Gln Thr (A3G72) (SEQ ID NO: 6), Lys-Phe-Leu-Glu-Gln-Lys-Ala-Pro-Arg-Asp-Ser-His (A4G73) (SEQ ID NO: 19), Gly Glu Lys Ser Gln Phe Ser He Arg Leu Lys Thr (A4G78) (SEO ID NO: 20), Thr Leu Phe-Leu Ala His-Gly Arg-Leu-Val-Phe Met (A4G82) (SEQ ID NO: 7), Thr-Leu-Phe Leu-Ala-His-Gly-Arg Leu-Val Phe-Nle (A4G82X) (SEQ ID NO: 8), Gly-Pro-Leu-Pro-Ser-Tyr-Leu-Gln-Phe-Val-Gly-Ile (A5G71) (SEO ID NO: 9), Arg-Asn-Arg-Leu-His-Leu-Ser-Met-Leu-Val-Arg-Pro (A5G73) (SEQ ID NO: 10), Arg Asn Arg Leu His Leu Ser NIe Leu Val Arg Pro (A5G73X) (SEQ ID NO: 11), Leu-Val-Leu-Phe-Leu-Asn-His-Gly-His-Phe-Val-Ala (A5G77) (SEQ ID NO: 12), Leu Val Leu Phe Leu Asn His Gly His (A5G77f) (SEQ ID NO: 13), Lys Asn Ser Phe-Met-Ala-Leu-Tyr-Leu-Ser-Lys-Gly (hA3G75) (SEQ ID NO: 21) or Gly-Asn-Ser-Thr-Ile-Ser-He-Arg-Ala-Pro-Val-Tyr (hA3G83) (SEQ ID NO: 15).

25. (Withdrawn) The solidified preparation according to claim 20, wherein the cell adhesion peptide is a peptide comprising 3 to 20 amino acid residues.

26. (Withdrawn) A method for producing a solidified preparation wherein a functional group, which is capable of reacting to a protein or a peptide, of a hydrophobic binding-adsorptive

Response to Notice of Non-Compliant Amendment Attorney Docket No. 053111

Art Unit: 1651

Application No. 10/551,052

polymer coated on a cell culture substrate reacts to a cell adhesion protein or peptide.

27. (Withdrawn) A method for producing a solidified preparation wherein a functional group,

which is capable of reacting to a protein or a peptide, of a hydrophobic binding-adsorptive

polymer reacts to a cell adhesion protein or peptide, and a cell culture substrate is coated with

the reactant.

28. (Withdrawn) A reactant obtained by reacting a functional group, which is capable of reacting

to a protein or a peptide, of a hydrophobic binding-adsorptive polymer, to cell adhesion proteins

or peptides.

29. (Withdrawn) An artificial tissue prepared by seeding a desired cell on the solidified

preparation of a cell adhesion protein or peptide according to any one of claims 17 to 27, and

culturing the cell.

30. (Withdrawn) The artificial tissue according to claim 29, wherein the desired cell is an

epithelial cell, an endothelial cell or a mesenchymal cell.

31. (Withdrawn) The artificial tissue according to claim 30, wherein the epithelial cell is an

epidermal cell, a corneal epithelial cell, an alveolar epithelial cell, a mucosal epithelial cell of

digestive system, a renal glomerular epithelial cell or a hepatic parenchymal cell.

- 18 -

Response to Notice of Non-Compliant Amendment Attorney Docket No. 053111

Art Unit: 1651

Application No. 10/551,052

32. (Withdrawn) The artificial tissue according to claim 30, wherein the endothelial cell is a

renal glomerular ciliated cell, a vascular endothelial cell, a pulmonary arterial vascular

endothelial cell, a placental venous vascular endothelial cell or an aortic endothelial cell.

33. (Withdrawn/Currently Amended) The artificial tissue according to claim 30, wherein the

mesenchymal cell is a muscle cell, an adipocyte, a glial cell, a Schwann cell or a neural cell

(neuron).

34. (Withdrawn) The artificial tissue according to any one of claims 29 to 33, wherein the

artificial tissue is an artificial epidermal tissue, an artificial corneal epithelial tissue, an artificial

alveolar epithelial tissue, an artificial respiratory epithelial tissue, an artificial renal glomerular

tissue, an artificial hepatic parenchymal tissue or an artificial vascular endothelial tissue, or an

artificial blood vessel, an artificial lung, an artificial liver, an artificial kidney, an artificial skin

or an artificial cornea

- 19 -